Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 49 Pancreatic Neoplasms 33 Prostatic Neoplasms 31 Brain Neoplasms 28 Lung Neoplasms 26 Neoplasm Metastasis 24 Melanoma 21 Carcinoma, Hepatocellular 20 Breast Neoplasms 16 Carcinoma, Renal Cell 12 Colorectal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Neoplasms 9 Small Cell Lung Carcinoma 7 Urinary Bladder Neoplasms 5 Recurrence 5 Head and Neck Neoplasms 5 Glioblastoma 5 Adenocarcinoma of Lung 5 Sarcoma 4 Liver Neoplasms 4 Kidney Neoplasms 4 Uterine Cervical Neoplasms 3 NSCLC 3 Clear-cell metastatic renal cell carcinoma 3 Cholangiocarcinoma 3 Uveal Melanoma 2 Unresectable Locally Recurrent Rectal Cancer 2 Rectal Neoplasms 2 Ovarian Neoplasms 2

Interventions

nimotuzumab 1 lenvatinib 1 atezolizumab 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × Radiosurgery × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡